OCHNCNP-1 is under clinical development by EA Pharma and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase II drugs for Secondary Progressive Multiple Sclerosis (SPMS) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OCHNCNP-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small molecule is under investigation for the treatment of Crohn’s disease, relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). It is administered through oral route. The drug candidate is an analogue of glycolipid α – galactosylceramide (α- GalCer).
EA Pharma overview
EA Pharma, formerly Ajinomoto Pharmaceuticals, a subsidiary of Eisai Co Ltd, is a clinical research organization that develops, manufactures and sells pharmaceutical products. The organization develops pharmaceutical products based on amino acid-related technologies for the treatment of gastrointestinal and metabolic diseases. Its pipeline products are used for ulcerative colitis, osteoporosis and chronic constipation diseases. EA Pharma provides drug discovery, production and logistics, sales and marketing, and research and development services. The organization serves various sectors such as medicine and healthcare. It markets its products through its network of distributors. EA Pharma is headquartered in Tokyo, Japan.
For a complete picture of OCHNCNP-1’s drug-specific PTSR and LoA scores, buy the report here.